alexa Castleman disease | Ireland | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

  • Annual Physicians Meeting 2018 May 11-12, 2018 Osaka, Japan
    May 11-12, 2018 Osaka, Japan
  • International Conference on Internal Medicine May 21-22, 2018 Osaka, Japan
    May 21-22, 2018 Osaka, Japan
  • 7th International Conference on Clinical and Medical Case Reports June 01-02, 2018 Osaka, Japan
    June 01-02, 2018 Osaka, Japan
  • ICACCM 2018 : 20th International Conference on Anesthesiology and Critical Care MedicineToronto, Canada June 21 - 22, 2018
    June 21-22, 2018 Dublin, Ireland
  • 7th International Conference and Exhibition on Surgery June 21-23, 2018 Dublin, Ireland
    June 21-23, 2018 Dublin, Ireland Dublin, Ireland

Relevant Topics

Castleman Disease

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Castleman disease

    Definition:
    Castleman disease is a rare disorder that involves an overgrowth (proliferation) of cells in your body's disease-fighting network (lymphatic system). Also known as giant lymph node hyperplasia and angiofollicular lymph node hyperplasia, Castleman disease can occur in a localized (unicentric) or widespread (multicentric) form.

  • Castleman disease

    Symptoms:
    Fever. Night sweats. Fatigue and weakness. Loss of appetite. Unintended weight loss. Enlarged lymph nodes, usually around the neck, collarbone, underarm and groin areas. Enlarged liver or spleen.

  • Castleman disease

    Statistics:
    About 72.7% of patients were male, and 27.3% were female. 63.6% of the patients were unicentric, and 36.4% were MC CD. 54.5% of the patients were managed with total excision, and 45.5% underwent incisional biopsy. About 63.6% of CD patients received RT and 27.3% were given only chemotherapy, whereas one patient (9.09%) received both RT and chemotherapy. Three-year survival was 83%, and 3-year disease free survival was 91%. No late toxicity was noted with. Acute toxicity was noted in two patients who received 45 Gy and no late radiation-induced toxicity was observed.

Expert PPTs

Speaker PPTs

 

High Impact List of Articles

Conference Proceedings